NCT02142075View on ClinicalTrials.gov

Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure

PHASE3CompletedINTERVENTIONAL

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2015

Conditions

Renal FailureCritical CareGram Positive Bacteria

Interventions

DRUG

Daptomycin

Trial Locations (4)

35033

Seguin P, University Hospital of Rennes, Rennes

37170

Ferrandiere M, University Hospital of Tours, Tours

44093

Asehnoune K, University Hospital of Nantes, Nantes

49933

Lasocki S, University Hospital of Angers, Angers

All Listed Sponsors

lead

Poitiers University Hospital

OTHER

NCT02142075 - Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure | Biotech Hunter | Biotech Hunter